Friday, January 13, 2023 10:35:27 AM
Recent PLSE News
- Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 • Business Wire • 05/02/2024 12:00:00 PM
- Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 • Business Wire • 04/24/2024 08:05:00 PM
- Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results • Business Wire • 03/28/2024 08:12:00 PM
- Pulse Biosciences Announces Plans to Initiate a Rights Offering • Business Wire • 03/28/2024 08:10:00 PM
- Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 • Business Wire • 03/14/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 01:10:42 PM
- Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System • Business Wire • 03/08/2024 06:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:22:18 PM
- Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study • Business Wire • 02/14/2024 01:00:00 PM
- Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium • Business Wire • 01/31/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 02:20:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 02:20:23 PM
- Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp • Business Wire • 01/02/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 02:08:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 02:06:34 PM
- Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter • Business Wire • 12/20/2023 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/27/2023 10:29:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 02:08:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2023 02:03:00 PM
- Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode • Business Wire • 11/21/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 02:11:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 02:10:09 PM
- Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference • Business Wire • 11/15/2023 09:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/13/2023 10:21:57 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 10:18:23 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM